See more : Bangfu Technology Group Co., Ltd. (BFGX) Income Statement Analysis – Financial Results
Complete financial analysis of Evoke Pharma, Inc. (EVOK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evoke Pharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Champ Ray (7642.TWO) Income Statement Analysis – Financial Results
- China Eastern Airlines Corporation Limited (CHEAF) Income Statement Analysis – Financial Results
- Tembo Gold Corp. (TBGPF) Income Statement Analysis – Financial Results
- Rio Tinto Group (RIO.SW) Income Statement Analysis – Financial Results
- Scottie Resources Corp. (SCTSF) Income Statement Analysis – Financial Results
Evoke Pharma, Inc. (EVOK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.evokepharma.com
About Evoke Pharma, Inc.
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.18M | 2.51M | 1.62M | 23.02K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 201.88K | 370.39K | 328.12K | 86.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.98M | 2.14M | 1.29M | -63.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 96.10% | 85.24% | 79.72% | -276.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 181.91K | 300.79K | 590.48K | 6.55M | 3.42M | 4.10M | 7.14M | 6.95M | 8.15M | 9.99M | 956.98K | 1.17M | 1.84M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 3.74M | 3.92M | 4.09M | 3.59M | 3.66M | 3.16M | 1.64M | 836.78K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.23M | 9.62M | 8.85M | 6.43M | 3.74M | 3.92M | 4.09M | 3.59M | 3.66M | 3.16M | 1.64M | 836.78K | 570.52K |
| Other Expenses | 0.00 | 370.39K | 328.12K | 86.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.41M | 9.92M | 9.44M | 12.98M | 7.15M | 8.01M | 11.23M | 10.54M | 11.82M | 13.15M | 2.60M | 2.00M | 2.41M |
| Cost & Expenses | 12.61M | 10.29M | 9.77M | 13.07M | 7.15M | 8.01M | 11.23M | 10.54M | 11.82M | 13.15M | 2.60M | 2.00M | 2.41M |
| Interest Income | 138.60K | 62.01K | 8.62K | 5.67K | 28.80K | 15.21K | 0.00 | 0.00 | 0.00 | 10.19K | 7.25K | 1.69K | 10.70K |
| Interest Expense | 500.00K | 500.00K | 500.05K | 112.99K | 0.00 | 15.21K | 6.52K | 268.03K | 0.00 | 107.83K | 159.89K | 24.04K | 2.87K |
| Depreciation & Amortization | 138.60K | 7.79M | 8.15M | 13.05M | 7.15M | 8.01M | 11.23M | 10.54M | 303.16K | 10.19K | 7.25K | 1.69K | 10.70K |
| EBITDA | -7.29M | -7.72M | -8.04M | -13.04M | 0.00 | 0.00 | 0.00 | 0.00 | -11.52M | -13.14M | -2.59M | -1.99M | -2.40M |
| EBITDA Ratio | -140.76% | -307.90% | -503.25% | -56,653.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.43M | -7.79M | -8.15M | -13.05M | -7.15M | -8.01M | -11.23M | -10.54M | -11.82M | -13.15M | -2.60M | -2.00M | -2.41M |
| Operating Income Ratio | -143.44% | -310.37% | -503.79% | -56,678.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -361.40K | -437.99K | -386.31K | -107.32K | 28.80K | 448.61K | -998.83K | -204.11K | -303.16K | -97.65K | -234.64K | -15.10K | 13.32K |
| Income Before Tax | -7.79M | -8.22M | -8.54M | -13.15M | -7.13M | -7.57M | -12.23M | -10.75M | -12.12M | -13.25M | -2.84M | -2.02M | -2.40M |
| Income Before Tax Ratio | -150.41% | -327.83% | -527.66% | -57,144.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -62.01K | 491.44K | 107.32K | -28.80K | -912.42K | -6.52K | 801.72K | 0.00 | 0.00 | 152.64K | 22.35K | -7.82K |
| Net Income | -7.79M | -8.16M | -9.03M | -13.26M | -7.10M | -7.57M | -12.23M | -10.75M | -12.12M | -13.25M | -2.84M | -2.02M | -2.40M |
| Net Income Ratio | -150.41% | -325.36% | -558.03% | -57,610.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -27.97 | -31.16 | -40.40 | -74.91 | -45.84 | -65.62 | -118.21 | -165.75 | -269.13 | -316.23 | -172.49 | -234.27 | -304.11 |
| EPS Diluted | -27.97 | -31.16 | -40.40 | -74.91 | -45.84 | -65.62 | -118.21 | -165.75 | -269.13 | -316.23 | -172.49 | -234.27 | -304.11 |
| Weighted Avg Shares Out | 278.59K | 261.97K | 223.51K | 177.03K | 154.83K | 115.29K | 103.46K | 64.85K | 45.04K | 41.89K | 16.44K | 8.61K | 247.43K |
| Weighted Avg Shares Out (Dil) | 278.59K | 261.97K | 223.51K | 177.03K | 154.83K | 115.29K | 103.46K | 64.85K | 45.04K | 41.89K | 16.44K | 8.61K | 247.43K |
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices...
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year
Ladbrokes and William Hill owners Entain and Evoke jump on Budget relief
Shares in bookmakers galloped higher after the UK Budget, led by Ladbrokes and Coral owner Entain PLC (LSE:ENT), which rose over 8%, and William Hill owner Evoke PLC, rising 12%. Paddy Power and Betfair owner Flutter Entertainment PLC (LSE:FLTR) also rose 6%.
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced upcoming poster presentations at the American College...
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced the appointment of Ben Smeal to serve...
Evoke reports first quarter of growth in over two years
William Hill and 888 owner Evoke PLC (LSE:EVOK) has reported a 3% increase in revenue to £417 million for the third quarter of 2024, compared to the same period last year. It highlighted that this marks its first quarter of...
Bookmakers Entain, Flutter, Evoke and Rank tumble on new gambling tax reports
Shares in listed bookmakers Entain PLC (LSE:ENT), Flutter Entertainment PLC (LSE:FLTR) and Evoke PLC (LSE:EVOK) tumbled on the back of news that the UK government might target the sector in this month's Budget. HM Treasury could hit the gambling industry with a £3 billion...
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal...
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis
XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry
SAN DIEGO--(BUSINESS WIRE)-- #CleanTech--EVoke Partnership.
Source: https://incomestatements.info
Category: Stock Reports